A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 2, 2014, Pages 137-149

  Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anticoagulants; Drug dosage calculations; Pharmacodynamics; Pharmacokinetics; Rivaroxaban; Thromboprophylaxis

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ARTICLE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SECONDARY PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM; ATRIAL FIBRILLATION; BLOOD; COMPLICATION; FEMALE; MALE;

ACUTE CORONARY SYNDROME; ATRIAL FIBRILLATION; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MORPHOLINES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84904768935     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1029-2     Document Type: Article

References (87)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:160S-198S (Pubitemid 351892967)
2. Hylek EM (2009) The need for new oral anticoagulants in clinical practice. J Cardiovasc Med (Hagerstown) 10:605-609
3. Dyke CK, Steinhubl SR, Kleiman NS et al (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of Factor IXa activity. Circulation 114:2490-2497 (Pubitemid 44901522)
4. Eriksson BI, Dahl OE, Lassen MR et al (2008) Partial Factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 6:457-463 (Pubitemid 351280113)
5. Goto S (2006) Factor XIa as a possible new target of antithrombotic therapy. J Thromb Haemost 4:1494-1495
6. Schumacher WA, Seiler SE, Steinbacher TE et al (2007) Antithrombotic and hemostatic effects of a small molecule Factor XIa inhibitor in rats. Eur J Pharmacol 570:167-174 (Pubitemid 47247686)
7. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F (2011) The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov 10:61-75
8. Bayer Pharma AG (2013) Xarelto® (rivaroxaban) summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000944/WC500057108.pdf. Accessed 15 Aug 2013
9. Boehringer Ingelheim International GmbH (2013) Pradaxa® (dabigatran etexilate) summary of product characteristics. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR---Product-Information/human/000829/WC500041059.pdf. Accessed 30 Apr 2013
10. Bristol-Myers S, Pfizer EEIG (2012) Eliquis® (apixaban) summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/002148/WC500107728.pdf. Accessed 30 April 2013
11. Boehringer Ingelheim Pharmaceuticals Inc (2012) Pradaxa® (dabigatran etexilate) prescribing information. http://www.accessdata.fda.gov/drugsatfda- docs/label/2012/022512s016lbl.pdf. Accessed 22 February 2013
12. Bristol-Myers Squibb Company, Pfizer Inc (2012) Eliquis® (apixaban) prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/202155s000lbl.pdf. Accessed 22 Feb 2013
13. Janssen Pharmaceuticals Inc (2012) Xarelto® (rivaroxaban) prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 022406s001s002s003lbl.pdf. Accessed 22 Feb 2013
14. Bayer HealthCare AG (2012) Bayer's xarelto® approved in Japan for stroke prevention in patients with non-valvular atrial fibrillation. http://healthcare.bayer.de. Accessed 22 Feb 2013
15. Pharmaceuticals and Medical Devices Agency (2010) Products approved in FY 2010: new drugs. http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2010. pdf. Accessed 12 Apr 2012
16. Bristol-Myers Squibb (2012) ELIQUIS® (apixaban) approved in Japan for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. http://news.bms.com/press-release/partnering-news/eliquis- apixaban-approved-japan-prevention-stroke-and-systemic-embolis&t= 634967931855219099. Accessed 22 Feb 2013
17. Raghavan N, Frost CE, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74-81
18. Pinto DJ, Orwat MJ, Koch S et al (2007) Discovery of 1-(4- methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6, 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation Factor Xa. J Med Chem 50:5339-5356 (Pubitemid 350057846)
19. Frost C, Yu Z, Moore K et al (2007) Apixaban, an oral direct Factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2):abstract P-M-664
20. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386-399 (Pubitemid 351185753)
21. Stangier J, Stähle H, Rathgen K, Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47-59 (Pubitemid 350260888)
22. Camm AJ, Bounameaux H (2011) Edoxaban: a new oral direct Factor Xa inhibitor. Drugs 71:1503-1526
23. Ogata K, Mendell-Harary J, Tachibana M et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743-753
24. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873-880 (Pubitemid 41803696)
25. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50:675-686
26. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 78:412-421 (Pubitemid 41393676)
27. Kubitza D, Becka M, Roth A, Mueck W (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24:2757- 2765
28. Boehringer Ingelheim (2011) Press release. http://www.boehringer- ingelheim.com/news/news-releases/press-releases/2011/21-january-2011- dabigatranetexilate.html. Accessed 12 May 2011
29. Pharmaceuticals and Medical Devices Agency (2011) Products approved in FY 2011: new drugs. http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2011. pdf. Accessed 12 April 2012
30. Sanofi-aventis US LLC (2011) Lovenox (enoxaparin sodium) prescribing information. http://products.sanofi-aventis.us/lovenox/lovenox.pdf. Accessed 28 Mar 2013
31. Ahrens I, Bode C (2012) Oral anticoagulation with edoxaban. Focus on current phase III clinical development. Hamostaseologie 32:212-215
32. Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9-19
33. Bristol-Myers Squibb Pharmaceuticals (2011) Sprycel (dasatinib) summary of product characteristics. http://www.ema.europa.eu/ docs/en-GB/document- library/EPAR---Product-Information/human/000709/WC500056998.pdf. Accessed 12 Jan 2012
34. Wang X, Hochhaus A, Kantarjian HM et al (2008) Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 26:175S
35. Shah NP, Kantarjian HM, Kim DW et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204-3212
36. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP (2013) Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study. Dovepress 5:85-97. http://www.dove press.com/differential-effects-of-dosing-regimen-on- the-safety-and- efficacy-of-d-peer-reviewed-article-CPAA-recommendation1. Accessed 18 June 2013
37. Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625-651
38. Weitz JI, Connolly SJ, Patel I et al (2010) Randomised, parallelgroup, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:633-641
39. Salazar DE, Mendell J, Kastrissios H et al (2012) Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 107:925-936
40. Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2007) Pharmacology of the oral, direct Factor Xa inhibitor rivaroxaban-effect of extreme age and gender. Hämostaseologie 27:A40 abstract P004
41. Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47:218-226 (Pubitemid 46146488)
42. Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk H (2007) Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban- an oral, direct Factor Xa inhibitor. J Thromb Haemost 5(Suppl 2):abstract P-M-635
43. Kubitza D, Becka M, Mueck W et al (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70:703-712
44. Graff J, von Hentig N, Misselwitz F et al (2007) Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 47:1398-1407 (Pubitemid 47624591)
45. Lang D, Freudenberger C, Weinz C (2009) In vitro metabolism of rivaroxaban-an oral, direct Factor Xa inhibitor-in liver microsomes and hepatocytes of rat, dog and man. Drug Metab Dispos 37:1046-1055
46. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D (2009) Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 37:1056-1064
47. Kreutz R (2012) Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 26:27-32
48. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M (2007) Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 45:335-344 (Pubitemid 46895052)
49. Mueck W, Eriksson BI, Bauer KA et al (2008) Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47:203-216
50. Mueck W, Borris LC, Dahl OE et al (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453-461
51. Turpie AGG, Esmon C (2011) Venous and arterial thrombosis- pathogenesis and the rationale for anticoagulation. Thromb Haemost 105:586-596
52. Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451:914-918
53. Hamm CW, Bassand JP, Agewall S et al (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999-3054
54. Steg PG, James SK, Atar D et al (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 33:2569-2619
55. Anderson JL, Adams CD, Antman EM et al (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e426-e579
56. Eriksson BI, Borris L, Dahl OE et al (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121-128
57. Turpie AGG, Fisher WD, Bauer KA et al (2005) BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3:2479-2486 (Pubitemid 41727165)
58. Eriksson BI, Borris LC, Dahl OE et al (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114:2374-2381 (Pubitemid 44847454)
59. Eriksson BI, Borris LC, Dahl OE et al (2007) Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685-693 (Pubitemid 47268049)
60. Agnelli G, Gallus A, Goldhaber SZ et al (2007) Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116:180-187 (Pubitemid 47057524)
61. Büller HR, Lensing AW, Prins MH et al (2008) A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 112:2242-2247
62. Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29-38
63. Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765-2775 (Pubitemid 351930851)
64. Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a doubleblind, randomised controlled trial. Lancet 372:31-39
65. Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776-2786 (Pubitemid 351930852)
66. Turpie AGG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673-1680
67. The EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499-2510
68. The EINSTEIN-PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287-1297
69. Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719-2747
70. Torbicki A, Perrier A, Konstantinides S et al (2008) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 29:2276-2315
71. Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e419S-e494S
72. You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e531S-e575S
73. ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159:340-347
74. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891
75. Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL (2009) Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 54:95-109
76. Eriksson BI, Kakkar AK, Turpie AGG et al (2009) Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 91:636-644
77. Turpie AGG, Lassen MR, Eriksson BI et al (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105:444-453
78. Turpie AGG, Schmidt A, Rud M et al (2012) Rivaroxaban for thromboprophylaxis after total hip or knee replacement surgery: comparison of outcomes of the XAMOS and RECORD studies. Blood 120:abstract 500
79. Fox KAA, Piccini JP, Wojdyla D et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32:2387-2394
80. Gibson CM (2011) Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 trial (ATLAS ACS 2-TIMI 51): a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. http://networking.americanheart.org/files/541. Accessed 27 June 2012
81. Merlini PA, Bauer KA, Oltrona L et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61-68 (Pubitemid 24203663)
82. Skeppholm M, Kallner A, Malmqvist K, Blombäck M, Wallén H (2011) Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 128:483-489
83. Falck-Ytter Y, Francis CW, Johanson NA et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e278S-e325S
84. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 23:83-91 (Pubitemid 46416852)
85. Amouyel P, Mismetti P, Langkilde LK, Jasso-Mosqueda G, Nelander K, Lamarque H (2009) INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 20:63-69
86. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R (2012) Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 28:669-680
87. Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS (2012) Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 29:675-690